Skip to content

#Psilocybin

19 NovThu
  1. Marijuana Moment (psychedelics policy only)42

    US House veterans committee holds hearing on psychedelic therapies for military veterans

    A US House Veterans' Affairs health subcommittee held a Wednesday hearing on veterans' access to psychedelic-assisted therapies, with VA officials and researchers testifying. The VA's Andrew Gradison said the department is running 21 active clinical studies on psychedelics, including an August-announced psilocybin trial in veterans with treatment-resistant depression.

17 NovTue
  1. Marijuana Moment (psychedelics policy only)40

    US House Veterans' Affairs health subcommittee to hold hearing on psychedelic-assisted therapies for veterans

    The House Veterans' Affairs Subcommittee on Health will hold a Wednesday hearing titled "Psychedelic-Assisted Therapies for Veterans: The Path Forward," with VA officials, medical professionals and researchers testifying. A VA official's written testimony says the department is conducting 21 active clinical studies on psychedelics, including a trial announced in August on psilocybin for veterans with treatment-resistant depression.

14 NovSat
  1. The Microdose (UC Berkeley BCSP)62

    FDA said to end priority voucher program as Compass Pathways files psilocybin application

    Reuters reported that the US Food and Drug Administration is ending the Commissioner's National Priority Voucher program, which had compressed a 10-12 month drug review to 1-2 months. Three psychedelics-related voucher holders are affected, including Compass Pathways' COMP360 for treatment-resistant depression, Usona Institute's psilocybin for major depressive disorder and Transcend Therapeutics' methylone for PTSD.

4 NovWed
2 NovMon
29 OctThu
  1. Lucid News58

    US federal health officials outline pre-approval groundwork for psychedelic medicines

    Officials from HHS, the FDA, the VA and ARPA-H described at The Psychedelic Healthcare Forum on Oct. 15 how an April executive order has reshaped federal preparation for psychedelic medicines. HHS Deputy General Counsel Matt Zorn said the order does not change statutory or regulatory standards, while the VA has designated 10 medical centres as Phase 1 lead sites and estimated around 100,000 veterans would qualify for psychedelic-assisted therapy immediately upon approval. The FDA's Dr Valentina Mantua said the agency oversees approximately 433 Investigational New Drug applications and has already requested REMS proposals from developers, and ARPA-H's Dr Al Bugazia cited cardiotoxicity and QTc prolongation risks, the lack of a domestic GMP manufacturer and a DEA manufacturing quota of just over 200 grams as obstacles for ibogaine research.

23 OctFri
  1. The Microdose (UC Berkeley BCSP)44

    ICER to review Compass Pathways' synthetic psilocybin COMP360 for treatment-resistant depression

    The Institute for Clinical and Economic Review announced on Wednesday it will evaluate the clinical effectiveness and cost of Compass Pathways' synthetic psilocybin COMP360 for treatment-resistant depression, with results to be discussed at the May 2027 meeting of the New England Comparative Effectiveness Public Advisory Council.

22 OctThu
9 OctFri
  1. Lucid News63

    New Mexico health department draft psilocybin rules draw rebuke at public hearing

    Medical providers, veterans, legal experts and the legislative sponsor of New Mexico's Medical Psilocybin Act criticised draft rules 7.35.3 and 7.35.2 NMAC at an Oct. 2 public hearing before the New Mexico Department of Health, arguing the proposed prescriber gateway, landlord consent requirements and staffing ratios exceed the statute and could block access. The department is accelerating the program's launch to December 2026, a year ahead of the statutory deadline. Speakers said the rules would require an in-person exam with a certifying clinician, patient identification cards and up to 30 days of state review, and that landlord sign-off for homebound patients and leased healing centres conflicts with fair housing law; some clinical educators praised the draft training and supervision standards. Sixteen advocacy and clinical organisations have asked Rep. Nathan P. Small to add $500,000 for the Treatment Equity Fund and $500,000 for University of New Mexico palliative research.

23 SepWed
18 SepFri
15 AugSat
8 JunMon
  1. TGA: interim scheduling decisions (Australia)62

    TGA publishes interim scheduling decisions on Poisons Standard amendments from ACMS #47 and Joint ACMS-ACCS #40

    The TGA has published its interim decisions on proposed amendments to the Poisons Standard considered at ACMS #47 and Joint ACMS-ACCS #40, and invites comment. The closing date for submissions is 10 July 2026. The notice is a summary only and does not list the substances or amendments covered.

    Why it matters: The notice marks the interim stage of scheduling, so anyone with an interest in the proposed Poisons Standard amendments has until 10 July 2026 to comment before a final decision.

28 MayThu
17 Dec 2025Wed
  1. TGA: interim scheduling decisions (Australia)58

    TGA publishes interim decisions on proposed Poisons Standard amendments from ACCS #40 and Joint ACMS-ACCS #39

    The TGA has published interim decisions on proposed amendments to the Poisons Standard arising from the Advisory Committee on Chemicals Scheduling (ACCS) #40 and the Joint Advisory Committee on Medicines Scheduling and Advisory Committee on Chemicals Scheduling (Joint ACMS-ACCS) #39. The notice invites comment, with a closing date of 23 January 2026. The feed gave no further detail on which substances or schedules the interim decisions cover.